house · trading 2015-11-02 → 2024-11-21
*Notional-weighted price return on disclosed buys from the last ~3 years, marked to the latest close — open positions, per-share (share counts aren't disclosed, so this is price performance, not realized $ P&L).
By recent-buy return, Doug Lamborn ranks #40 of 122 lawmakers — better than 67% of Congress.
▮ buys · ▮ sells
| Date | Ticker | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2024-11-21 | SPY | SELL | $1K–$15K | $593.67 | $771.10 2026-08-27 | +3.6% rt |
| 2024-11-21 | SPY | BUY | $1K–$15K | $593.67 | $771.10 2026-08-27 | +29.9% |
| 2024-11-21 | ITB | SELL | $1K–$15K | $118.45 | $95.63 2026-08-27 | +19.3% exit |
| 2024-10-04 | SPY | BUY | $1K–$15K | $572.98 | $771.10 2026-08-27 | +34.6% |
| 2024-07-24 | SP | BUY | $1K–$15K | — | — | — |
| 2024-07-24 | NTAP | SELL | $1K–$15K | $125.70 | $190.64 2026-08-27 | +121.2% rt |
| 2024-07-24 | NTAP | BUY | $1K–$15K | $125.70 | $190.64 2026-08-27 | +51.7% |
| 2024-07-22 | SP | BUY | $1K–$15K | — | — | — |
| 2024-03-20 | SP | SELL | $1K–$15K | — | — | — exit |
| 2024-03-20 | SP | BUY | $1K–$15K | — | — | — |
| 2024-03-20 | META | BUY | $1K–$15K | $505.52 | $571.10 2026-08-27 | +13.0% |
| 2024-03-01 | META | BUY | $1K–$15K | $502.30 | $571.10 2026-08-27 | +13.7% |
| 2023-12-06 | NTAP | SELL | $1K–$15K | $89.40 | $190.64 2026-08-27 | +29.7% rt |
| 2023-12-01 | NTAP | BUY | $1K–$15K | $91.28 | $190.64 2026-08-27 | +108.8% |
| 2023-07-07 | NTAP | BUY | $1K–$15K | $76.25 | $190.64 2026-08-27 | +150.0% |
| 2023-06-05 | TREA | SELL | $1K–$15K | — | — | — exit |
| 2023-06-05 | NTAP | SELL | $1K–$15K | $70.28 | $190.64 2026-08-27 | -7.7% rt |
| 2023-06-05 | NTAP | BUY | $50K–$50K | $70.28 | $190.64 2026-08-27 | +171.3% |
| 2023-06-05 | NTAP | BUY | $1K–$15K | $70.28 | $190.64 2026-08-27 | +171.3% |
| 2022-11-07 | SP | BUY | $1K–$15K | — | — | — |
| 2022-08-29 | SP | BUY | $1K–$15K | — | — | — |
| 2022-08-17 | SP | BUY | $1K–$15K | — | — | — |
| 2022-08-15 | SP | BUY | $1K–$15K | — | — | — |
| 2022-08-04 | SP | BUY | $1K–$15K | — | — | — |
| 2022-07-25 | NTAP | BUY | $1K–$15K | $69.17 | $190.64 2026-08-27 | +175.6% |
| 2022-07-19 | NTAP | BUY | $1K–$15K | $68.31 | $190.64 2026-08-27 | +179.1% |
| 2022-07-18 | NTAP | BUY | $1K–$15K | $65.57 | $190.64 2026-08-27 | +190.7% |
| 2022-07-18 | META | BUY | $1K–$15K | $167.23 | $571.10 2026-08-27 | +241.5% |
| 2022-06-06 | SP | BUY | $1K–$15K | — | — | — |
| 2021-11-09 | SP | SELL | $1K–$15K | — | — | — exit |
| 2021-11-09 | SP | BUY | $1K–$15K | — | — | — |
| 2021-11-08 | SP | SELL | $1K–$15K | — | — | — exit |
| 2021-11-08 | SP | BUY | $1K–$15K | — | — | — |
| 2021-10-26 | SP | BUY | $1K–$15K | — | — | — |
| 2021-10-26 | NTAP | SELL | $1K–$15K | $90.66 | $190.64 2026-08-27 | +5.5% rt |
| 2021-10-26 | NTAP | BUY | $1K–$15K | $90.66 | $190.64 2026-08-27 | +110.3% |
| 2021-10-25 | SP | BUY | $1K–$15K | — | — | — |
| 2021-10-25 | NTAP | BUY | $1K–$15K | $93.10 | $190.64 2026-08-27 | +104.8% |
| 2021-06-01 | SP | BUY | $1K–$15K | — | — | — |
| 2021-05-28 | SP | BUY | $1K–$15K | — | — | — |
| 2021-05-17 | SP | BUY | $1K–$15K | — | — | — |
| 2021-05-12 | SP | BUY | $1K–$15K | — | — | — |
| 2021-05-10 | SP | BUY | $1K–$15K | — | — | — |
| 2021-04-26 | SP | BUY | $1K–$15K | — | — | — |
| 2021-04-20 | SP | BUY | $1K–$15K | — | — | — |
| 2021-03-19 | NTAP | BUY | $1K–$15K | $70.16 | $190.64 2026-08-27 | +171.7% |
| 2021-02-16 | NTAP | BUY | $1K–$15K | $68.85 | $190.64 2026-08-27 | +176.9% |
| 2021-02-08 | GSK | BUY | $1K–$15K | $35.46 | $50.27 2026-08-27 | +41.8% |
| 2020-12-30 | META | BUY | $1K–$15K | $271.87 | $571.10 2026-08-27 | +110.1% |
| 2020-12-28 | NET | BUY | $1K–$15K | $77.50 | $308.23 2026-08-27 | +297.7% |
Return: buys are marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (how the stock moved after the sale, seller's perspective).
| Member | Shared tickers |
|---|---|
| Rohit Khanna | 5 · NTAP, SP, META, GSK, SPY |
| John Boozman | 4 · NTAP, META, GSK, SPY |
| Mike Kelly | 4 · SP, META, GSK, SPY |
| Josh Gottheimer | 3 · NET, META, SPY |
| Thomas R Carper | 3 · NTAP, GSK, SPY |
| Rob Bresnahan | 3 · NET, META, SPY |
| James B. Renacci | 2 · GSK, SPY |
| Thomas H Tuberville | 2 · META, GSK |
| Virginia Foxx | 2 · GSK, NAT |
| K. Michael Conaway | 2 · GSK, SPY |
| Kurt Schrader | 2 · GSK, SPY |
| David P. Roe | 2 · META, GSK |